HC Wainwright & Co. Reiterates Buy on Travere Therapeutics, Maintains $67 Price Target

Benzinga Newsdesk www.benzinga.com Neutral 89.9%

Neg 0% Neu 89.9% Pos 0%

HC Wainwright & Co. analyst Joseph Pantginis reiterates Travere Therapeutics (NASDAQ:TVTX) with a Buy and maintains $67 price target.